Medically reviewed by Drugs.com. Last updated on Feb 11, 2019.
(la TA noe prost)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Xelpros: 0.005% (2.5 mL) [contains edetate disodium, propylene glycol]
Xalatan: 0.005% (2.5 mL) [contains benzalkonium chloride]
Generic: 0.005% (2.5 mL)
Brand Names: U.S.
- Ophthalmic Agent, Antiglaucoma
- Prostaglandin, Ophthalmic
Latanoprost is a prostaglandin F2-alpha analog believed to reduce intraocular pressure by increasing the outflow of the aqueous humor
Through the cornea where the isopropyl ester prodrug is hydrolyzed by esterases to the biologically active acid. Peak concentration is reached in 2 hours after topical administration in the aqueous humor.
Vd: 0.16 ± 0.02 L/kg
Primarily hepatic via fatty acid beta-oxidation
Urine (as metabolites)
Onset of Action
3 to 4 hours; Peak effect: Maximum: 8 to 12 hours
Use: Labeled Indications
Elevated intraocular pressure: Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension.
Hypersensitivity to latanoprost, benzalkonium chloride, or any component of the formulation
Elevated intraocular pressure: Ophthalmic: One drop in the affected eye(s) once daily in the evening; do not exceed the once daily dosage (may decrease the IOP-lowering effect)
Refer to adult dosing.
Reduction of intraocular pressure: Limited data available: Infants, Children, and Adolescents: 1 drop to affected eye(s) once daily in the evening (Maeda-Chubachi 2013; Quaranta 2017)
Ophthalmic: May be used with other eye drops to lower IOP. If more than one topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart. Remove contact lenses prior to administration and wait 15 minutes before reinserting.
Emulsion: Store at 2°C to 25°C (36°F to 77°F). Protect from light. May be maintained at temperatures up to 40°C (104°F) for up to 8 days during shipment.
Solution: Store intact bottles under refrigeration at 2°C to 8°C (36°F to 46°F). Protect from light. Once opened, the container may be stored at room temperature up to 25°C (77°F) for 6 weeks.
Bimatoprost: The concomitant use of Latanoprost and Bimatoprost may result in increased intraocular pressure. Monitor therapy
Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). Monitor therapy
Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the therapeutic effect of Prostaglandins (Ophthalmic). Monitor therapy
Central nervous system: Foreign body sensation of eye (2% to 13%)
Ophthalmic: Eye pain (≤55%), stinging of eyes (≤55%), ocular hyperemia (41%), conjunctival hyperemia (8% to 15%), eye discharge (12%), increased eyelash length (11%)
1% to 10%:
Dermatologic: Erythema of eyelid (3%), hyperpigmentation of eyelashes (1%), allergic skin reaction (≤1%, including eyelid), skin rash (≤1%)
Infection: Influenza (≤3%)
Neuromuscular & skeletal: Arthralgia (≤1%), back pain (≤1%), myalgia (≤1%)
Ophthalmic: Punctate keratitis (1% to 10%), blurred vision (8%), increased eyelash thickness (8%), eye pruritus (5% to 8%), burning sensation of eyes (7%), iris hyperpigmentation (7%), decreased visual acuity (4%), eyelid pain (4%), lacrimation (4%), crusting of eyelid (3%), dry eye syndrome (3%), photophobia (2%), eyelid edema (1% to 2%), conjunctival edema (1%)
Respiratory: Nasopharyngitis (≤3%), upper respiratory tract infection (≤3%)
<1%, postmarketing, and/or case reports: Angina pectoris, asthma, bacterial keratitis, chest pain, conjunctivitis (including pseudopemphigoid of the ocular conjunctiva), corneal edema, corneal erosion, dizziness, dyspnea, exacerbation of asthma, eye disease (periorbital and lid changes resulting in deepening of the eyelid sulcus), headache, herpes simplex keratitis, hyperpigmentation of eyelids, increased growth in number of eyelashes, iris cyst, iritis, keratitis, macular edema (including cystoid macular edema), misdirected growth of eyelashes (including trichiasis), palpitations, pruritus, toxic epidermal necrolysis, unstable angina pectoris, uveitis
Concerns related to adverse effects:
• Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions, has caused bacterial keratitis.
• Ocular effects: May change/increase brown pigmentation of the iris, the eyelid skin, and eyelashes; length and/or number of eyelashes may also be increased. Pigmentation of the iris is likely to be permanent although iris color change may not be noticeable for months to years; pigmentation of the periorbital tissue and eyelash changes may be reversible following discontinuation of therapy. Long-term consequences and potential injury to eye are not known.
• Ocular inflammation: Intraocular inflammation and exacerbation of inflammation may occur; use with caution in patients with a history of intraocular inflammation (eg, iritis/uveitis) and generally avoid use in patients with active intraocular inflammation.
• Herpetic keratitis: Use with caution in patients with a history of herpes simplex keratitis; reactivation may occur. Avoid use in patients with active herpes simplex keratitis.
• Ocular disease: Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema. Safety and efficacy have not been determined for use in patients with angle-closure, inflammatory, or neovascular glaucoma.
• Contact lens wearers: Solution contains benzalkonium chloride which may be absorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.
Monitor IOP; regularly examine patients who develop increased iris pigmentation.
Information related to use in pregnancy is limited (DeSantis 2004).
In general, if ophthalmic agents are needed in pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease exposure to the fetus (Samples 1988).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience blurred vision, burning, stinging, eyelash changes, or foreign body sensation in eye. Have patient report immediately to prescriber vision changes, eye pain, severe eye irritation, eye discharge, or eye discoloration (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about latanoprost ophthalmic
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 25 Reviews
- Drug class: ophthalmic glaucoma agents